Improvement of gastrointestinal symptoms taking Rebamipide in type 2 diabetes
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0001220
- Lead Sponsor
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
1. inclusive criteria
1)18~80 years old
2)type 2 diabetes patients with abdominal pain or discomfort, bloating,burnig sense,irritable bowel symptom
3)HbA1c <10% within 3 months during study period
4)no dose changes of drugs that could affect gastrointestinal symptoms within 3 months during study period
- PPI, H2 blocker,
- prokinetic agents such as Domperidone, Gasmotin, Metoclopromide
Exclusive criteria
1)Impossible communication
2)Patients with psychotic disorders without cooperation
3)Patients with severe heart disease
4)Patients with severe renal disease
5)Patients with severe liver disease
6)Patients with severe lung disease
7)Diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome history
8)Patients with diabetic fool who need treatment immediately
9)Malignancy
10)Pregnancy or lactation
11)Hyperresponsive to clinical drugs
12)Patients who participated in other studies within 30 days before registration
13)Alcohol or drug abuse
14)Patients without agreement to this test plan
15)Hard to undergo this trial Judgmented by doctor
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change of gastrointestinal symptomatic Questionnaire
- Secondary Outcome Measures
Name Time Method side effect